Abstract
Apparently, unexplained weight loss is a common symptom experienced by patients affected by Parkinson’s disease, especially in those treated by levodopa–carbidopa infusion gel (LCIG) with a poor control of dyskinesias. Weight loss is considered part of gastrointestinal dysfunction seen in patients affected by Parkinson’s disease, along with gastroparesis and reduced bowel peristalsis. In patients treated with LCIG, weight loss needs to be accurately evaluated, because of possible underlying life-threatening adverse events, like duodenum decubitus ulcer.
This is a preview of subscription content, log in via an institution to check access.
References
Abbott RA, Cox M, Markus H, Tomkins A (1992) Diet, body size and micronutrient status in Parkinson’s disease. Eur J Clin Nutr 46(12):879–884
Antonini A, Odin P, Tomantschger V, Pacchetti C, Pickut B, Gasser UE et al (2013) Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm 120(11):1553–1558
Antonini A, Yegin A, Preda C, Bergmann L, Poewe W (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat D 21(3):231–235
Braak H, de Vos RA, Bohl J, Del Tredici K (2006) Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396(1):67–72
Buongiorno M, Antonelli F, Cámara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J et al (2015) Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat D 21(8):871–876
Calandrella D, Romito LM, Elia AE, Del Sorbo F, Bagella CF, Falsitta M, Albanese A (2015) Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology 84(16):1669–1672
Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF (2015) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 14(6):625–639
Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Movement Disord 30(4):500–509
Olivares A, Collado D, Muñoz-Navas M, Calvo M, Olivo E, Chico I et al (2012) Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson’s disease. Gastroenterol Insights 4:e4
Pålhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J et al (2012) Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126(6):e29–e33
Papapetropoulos S, Mash DC (2007) Motor fluctuations and dyskinesias in advanced/end stage Parkinson’s disease: a study from a population of brain donors. J Neural Transm 114(3):341–345
Pfeiffer RF (2011) Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat D 17(1):10–15
Schrag A, Horsfall L, Walters K, Noyce A, Petersen I (2015) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14(1):57–64
Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D, Capone JG et al (2014) Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J Neural Transm 121(6):633–642
Visanji NP, Marras C, Hazrati LN, Liu LW, Lang AE (2014) Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson’s disease biomarker. Movement Disord 29(4):444–450
Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D et al (2014) Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol 21(2):312–318
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Martino, T., Melchionda, D., Tonti, P. et al. Weight loss and decubitus duodenal ulcer in Parkinson’s disease treated with levodopa–carbidopa intestinal gel infusion. J Neural Transm 123, 1395–1398 (2016). https://doi.org/10.1007/s00702-016-1618-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-016-1618-2